Recent News

BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, January 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical trials of Bria-IMT™ (formerly referred to as SV-BR-1-GM). BriaCell currently is enrolling patients in two separate but […]

News and Events, Recent News

BriaCell To Attend Biotech Showcase™ 2018

BERKELEY, Calif. and VANCOUVER, British Columbia, January 2, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at Hilton San Francisco Union Square (333 O’Farrell St, […]

News and Events, Recent News

Dr. Bill Williams Guest Appearance at “CEO Money” Radio Show

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams, BriaCell’s President & CEO, will appear as a guest on the radio show “CEO MONEY.” CEO MONEY, […]

News and Events, Recent News

BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance

BERKELEY, Calif. and VANCOUVER, British Columbia, November 13, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent […]

News and Events, Recent News

BriaCell Provides Clinical Update

BERKELEY, Calif. and VANCOUVER, British Columbia, November 6, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax™, in advanced breast cancer patients. […]

News and Events, Recent News

FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to their Immunotherapy in Patients with Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct 30, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, announced today that the FDA has approved the roll-over combination study of BriaVax™ with pembrolizumab {Keytruda; manufactured by Merck & Co., Inc. (NYSE: MRK)} […]

News and Events, Recent News

BriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 25, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening of a third clinical site. Jason Lukas, MD, PhD, a Board-Certified Oncologist – experienced with breast cancer vaccines […]

News and Events, Recent News

BriaCell Provides Research Update

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 14, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to provide an update on its collaborative and internal research as well as manufacturing activities. Collaborations The Company has recently initiated a […]

News and Events, Recent News

BriaCell Provides A Corporate Update

Berkeley, CA and Vancouver, BC – September 12, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is to provide a Corporate Update for the existing and potential shareholders. Dr. Williams, BriaCell’s President & CEO will provide an update on BriaVax™ […]